Humulin M3

Humulin M3 is a pharmaceutical product containing the active ingredient insulin human. It is supplied in an injectable form for intramuscular or subcutaneous administration. As a recombinant human insulin, Humulin M3 is classified as an antidiabetic drug and is available by prescription in the European market. The preparation provides a source of insulin to replace or supplement endogenous type hormone in patients with diabetes mellitus.

Humulin M3 is indicated for the management of blood glucose levels in individuals diagnosed with diabetes mellitus.

- Initiation of insulin therapy in patients whose endogenous insulin production is insufficient. - Replacement therapy for type 1 diabetes when pancreatic beta‑cell function is absent. - Supplemental insulin for type 2 diabetes patients who have not achieved glycemic targets with oral agents. - Peri‑operative glucose control in surgical patients with diabetes. - Management of gestational diabetes when diet and oral agents are inadequate. - Adjustment of basal insulin requirements during periods of illness or stress.

Adverse reactions to Humulin M3 may vary in frequency and severity, ranging from mild injection‑site discomfort to rare but serious systemic events.

Common: - Localized pain, redness, or swelling at the injection site. - Mild hypoglycemia presenting as shakiness, sweating, or hunger. - Transient weight gain due to fluid retention. - Injection site bruising or hematoma that resolves spontaneously. - Nausea or mild gastrointestinal discomfort after dosing.

Serious: - Severe hypoglycemia with confusion, loss of consciousness, or seizures. - Allergic reactions such as urticaria, angioedema, or anaphylaxis. - Lipodystrophy or lipoatrophy at repeated injection sites. - Edema or congestive heart failure exacerbation in patients with pre‑existing cardiac disease.

When prescribing or using Humulin M3, clinicians and patients should observe several precautionary measures to minimize risk and ensure appropriate therapy.

- Assess renal and hepatic function before initiating therapy, as impairment may alter insulin clearance. - Monitor blood glucose regularly to avoid hypoglycemia, especially during dose adjustments. - Educate patients on proper injection technique and site rotation to prevent lipodystrophy. - Review concomitant use of other antidiabetic agents for additive hypoglycemic potential. - Consider pregnancy status; insulin requirements may change during gestation. - Advise patients to report signs of allergic reaction, such as rash or swelling, promptly.

Humulin M3 can interact with other medicines or substances that affect glucose metabolism or insulin action, requiring careful management.

Avoid: - Concurrent use of sulfonylureas or meglitinides, which may precipitate profound hypoglycemia. - High‑dose beta‑blockers that mask hypoglycemia symptoms. - Corticosteroids administered systemically, as they can markedly increase insulin requirements. - MAO inhibitors, which may interfere with carbohydrate metabolism and increase insulin sensitivity.

Use with caution: - Loop or thiazide diuretics, which can alter electrolyte balance and affect insulin sensitivity. - ACE inhibitors or ARBs, which may potentiate insulin’s glucose‑lowering effect. - Alcohol consumption, especially in excess, as it can cause unpredictable glucose fluctuations. - Thyroid hormone replacement therapy, as altered metabolic rate can modify insulin needs.